James P. Flynn - 15 Dec 2022 Form 4 Insider Report for ARCA biopharma, Inc. (ORKA)

Role
Director
Signature
/s/ C. Jeffrey Dekker, Attorney-in-Fact
Issuer symbol
ORKA
Transactions as of
15 Dec 2022
Net transactions value
$0
Form type
4
Filing time
19 Dec 2022, 15:19:58 UTC
Next filing
03 Nov 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABIO Stock Option (right to buy) Award $0 +12,000 $0.000000 12,000 15 Dec 2022 Common Stock 12,000 $2.32 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 36 equal monthly installments beginning as of December 15, 2022. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested.